EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults

Andras Nagy iD, Kimberly Duff iD, Alexander Bauer iD, Fred Okonneh iD, Juan Carlos Rondon, Leman Yel iD, Zhaoyang Li iD

Journal of Clinical Immunology · 2024

DOI: 10.1007/s10875-023-01632-2 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Andras Nagy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria. Hauptthemen laut MEDLINE: Hyaluronoglucosaminidase, Immunoglobulin G. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, a Takeda company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 20% will allow reduced infusion volumes and frequency versus existing subcutaneous therapies such as fSCIG 10% and conventional subcutaneous immunoglobulin 20%, respectively. We assessed the tolerability, safety, and immunogenicity of warmed and unwarmed fSCIG 20%.

Methods

This phase 1, single-dose, open-label, three-arm study enrolled healthy adults aged 19–50 years (inclusive) at a single US center (NCT05059977). Post-screening, participants received a single fSCIG 20% dose comprising recombinant human hyaluronidase and varying doses of in-line warmed or unwarmed immunoglobulin G (IgG) during a 4-day treatment period in a sentinel and sequential dosing design (treatment arm 1, warmed IgG 20% 0.4 g/kg; treatment arm 2, warmed IgG 20% 1.0 g/kg; treatment arm 3, unwarmed IgG 20% 1.0 g/kg). Participants were followed for 12 (± 1) weeks post-infusion. The primary endpoint was tolerability (“tolerable” infusions were not interrupted, stopped, or reduced in rate owing to fSCIG 20%-related treatment-emergent adverse events (TEAEs)). Secondary endpoints included occurrence of TEAEs.

Results

Overall, 24 participants were included, 8 per treatment arm (mean age 39.0 years, 54.2% men). All participants tolerated the infusions. All TEAEs were mild (107 events, in all participants), and all participants experienced fSCIG 20%-related (105 events) and local (102 events) TEAEs. Infusion site erythema and infusion site swelling were most frequently reported. No serious TEAEs occurred, and no participants discontinued the study owing to TEAEs. Conclusion fSCIG 20% was well-tolerated with a favorable safety profile in healthy adults. Future studies will evaluate fSCIG 20% in primary immunodeficiency diseases. Trial registration number (ClinicalTrials.gov): NCT05059977 (registered 28 September 2021).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyaluronoglucosaminidaseImmunoglobulin GMaleAdultHumansFemaleInjections, SubcutaneousInfusions, SubcutaneousClinical Protocols

Stichwörter der Autor:innen

Hyaluronidase-facilitated subcutaneous immunoglobulin 20%inborn errors of immunityprimary immunodeficiency diseaserecombinant human hyaluronidasesafetytolerability

Substanzen

HyaluronoglucosaminidaseImmunoglobulin G

Autor:innen und Institutionen

  • Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria.
  • Takeda Development Center Americas, Inc., Cambridge, MA, USA.
  • Clinical Pharmacology of Miami, LLC, an Evolution Research Group portfolio company, Miami, FL, USA.
  • University of California, Irvine, CA, USA.
  • Takeda Development Center Americas, Inc., Cambridge, MA, USA. zhaoyang.li@takeda.com.

ORCID-Profile: Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Leman Yel, Zhaoyang Li

Förderung

  • Takeda Development Center Americas, Inc.
  • Baxalta Innovations GmbH, a Takeda company

Zitieren

APA

Nagy, A., Duff, K., Bauer, A., Okonneh, F., Rondon, J. C., Yel, L., & Li, Z. (2024). A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-023-01632-2

Vancouver

Nagy A, Duff K, Bauer A, Okonneh F, Rondon JC, Yel L, et al. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-023-01632-2

BibTeX
@article{Nagy2024,
  author = {Nagy, Andras and Duff, Kimberly and Bauer, Alexander and Okonneh, Fred and Rondon, Juan Carlos and Yel, Leman and Li, Zhaoyang},
  title = {A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults},
  journal = {Journal of Clinical Immunology},
  year = {2024},
  doi = {10.1007/s10875-023-01632-2}
}
Kostenlos starten →